Simon Klimovic

Simon Klimovic

Auto-generated profile, based on publicly available information

Simon Klimovic

Central European Institute for Technology, Masaryk University, Kamenice 753/5, 625 00, Brno, Czech Republic

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2022 in Micron
Verified
Journal Article
Closed access
DKDaniil Kabanov
Daniil Kabanov
SKSimon Klimovic
Simon Klimovic
VRVladimir Rotrekl
Vladimir Rotrekl
MPMartin Pesl
Martin Pesl
JPJan Pribyl
Jan Pribyl

9 November 2025 in Analytica Chimica Acta
Verified
Journal Article
Open access
FSFilip Svěrák
Filip Svěrák
DKDaniil Alexsandrovich Kabanov
Daniil Alexsandrovich Kabanov
ŠVŠimon Vrana
Šimon Vrana
DBDeborah Beckerova
Deborah Beckerova
JMJan Machal
Jan Machal
JPJan Pribyl
Jan Pribyl
Accurate detection of conduction disorders, a critical factor for arrhythmogenic risk assessment, is a key challenge in drug development and cardiovascular safety screening. This study presents a highly sensitive atomic force microscopy (AFM)-based biosensor using a dual-beating human pluripotent stem cell (hPSC)-derived organoid to discriminate between focal and conductive arrhythmic contractions. Analysis of the variance of the regression residuals revealed increased stochastic (random) fluctuations in unsynchronized clusters, indicative of arrhythmic instability. Mechanosensing assessed by force microscopy allows the differentiation of the vertical and lateral direction of contractile movement. The high biosensor sensitivity allowed detailed analysis of contractile behavior under pharmacological modulation with cardiomodulating drugs. Moreover, heptanol-induced arrhythmias were associated with inhibition of atrioventricular conduction, demonstrating the ability of the system to model mechanisms of conduction blockade. For the first time, an AFM-based transducer successfully discriminates focal from conductive arrhythmias, marking a significant advance in vitro cardiac biosensing. The dual organoid system enhances model robustness by reducing the variability inherent in single-cell studies, thereby improving translational relevance for cardiotoxicity assessment and precision medicine applications in cardiovascular health.

9 November 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DKDaniil Alexsandrovich Kabanov
Daniil Alexsandrovich Kabanov
SKSimon Vrana Klimovic
Simon Vrana Klimovic
DBDeborah Beckerova
Deborah Beckerova
MMMartin Molcan
Martin Molcan
MSMartin Scurek
Martin Scurek
MPMartin Pesl
Martin Pesl
The combination of aminophylline and salbutamol is frequently used in clinical practice in the treatment of obstructive lung diseases. While the side effects (including arrhythmias) of the individual bronchodilator drugs were well described previously, the side effects of combined treatment are almost unknown. We aimed to study the arrhythmogenic potential of combined aminophylline and salbutamol treatment in vitro. For this purpose, we used the established atomic force microscopy (AFM) model coupled with cardiac organoids derived from human pluripotent stem cells (hPSC-CMs). We focused on the chronotropic, inotropic, and arrhythmogenic effects of salbutamol alone and aminophylline and salbutamol combined treatment. We used a method based on heart rate/beat rate variability (HRV/BRV) analysis to detect arrhythmic events in the hPSC-CM based AFM recordings. Salbutamol and aminophylline had a synergistic chronotropic and inotropic effect compared to the effects of monotherapy. Our main finding was that salbutamol reduced the arrhythmogenic effect of aminophylline, most likely mediated by endothelial nitric oxide synthase activated by beta-2 adrenergic receptors. These findings were replicated and confirmed using hPSC-CM derived from two cell lines (CCTL4 and CCTL12). Data suggest that salbutamol as an add-on therapy may not only deliver a bronchodilator effect but also increase the cardiovascular safety of aminophylline, as salbutamol reduces its arrhythmogenic potential.

20 May 2022 in Analytica Chimica Acta
Verified
Journal Article
Closed access
RPRoberto Pivato
Roberto Pivato
SKSimon Klimovic
Simon Klimovic
DKDaniil Kabanov
Daniil Kabanov
FSFilip Sverák
Filip Sverák
MPMartin Pesl
Martin Pesl
VRVladimir Rotrekl
Vladimir Rotrekl